Ventas offers durable longevity-economy growth and improving SHOP economics, but its 25.8x forward P/FFO multiple and refinancing exposure demand disciplined execution.
Overview
Ventas is a diversified healthcare REIT with more than 1,400 North American and U.K. properties spanning senior housing, outpatient medical offices, research laboratories, and triple-net assets. Its two principal revenue engines are resident fees and services in SHOP communities and contractual rental income from medical, research, and NNN properties. **The central investment case is a favorable senior-housing demand-supply imbalance:** the 80-plus population is projected to grow nearly 30% over five years, while senior housing starts remained severely constrained at approximately 1,500 units in early 2026. Q1 2026 revenue rose 22.0% year over year to $1.657 billion, beat consensus by approximately $67 million, and Normalized FFO per share increased 9.3% to $0.94, exceeding consensus by $0.03. Management raised 2026 Normalized FFO guidance to $3.82-$3.89 per share and senior housing investment guidance to $3.0 billion. The offset is valuation and leverage: Ventas trades at approximately 25.8x forward P/FFO, with 5.0x net debt/Adjusted EBITDA and BBB+/Baa1 ratings versus Welltower’s 2.73x and A-/A3. The near-term catalyst is execution on acquisitions and SHOP margin expansion, with Q2 2026 FFO projected at $0.96 per share.